Even in the absence of drug resistance, parasite recurrence can occur, owing to high parasite densities, low host immunity, or suboptimal drug concentrations. Malaria elimination is firmly back as a mainstream policy but resistance to the artemisinin derivatives, their partner drugs, and insecticides present major challenges. on the actual malaria drug resistance status on the Cambodia-Thailand border. The consultation aimed to explore underlying reasons for the emergence of drug resistance and to set up and deploy a comprehensive and multi-sector strategy to halt the development and prevent the further spread of malaria drug resistance. continued use of drugs whose effectiveness have been compromised by drug resistance. The potential value of malaria therapy using combinations of drugs (5-9) was identified as a strategic and viable option in improving efficacy, and delaying development and selection of resistant parasites. Malaria can be treated effectively early in the course of the disease, but delay of therapy can have serious or even fatal consequences. Specific treatment options depend on the species of malaria, the severity of infection, the likelihood of drug resistance (based on where the infection was acquired), and the patient's age and pregnancy status. One of the fundamental steps toward malaria control is the use of antimalarial drugs. The success of antimalarial treatment can be affected by the presence of drug-resistant populations of Plasmodium falciparum. To assess resistance, we used molecular methods to examine 351 P. falciparum isolates collected from 4 sentinel sites in Mozambique for K13, pfmdr1, pfcrt, and pfdhps polymorphisms and ANTI-MALARIA DRUG POLICY FOR GHANA MINISTRY OF HEALTH 2 In Ghana, as well as globally, malaria control programmes are threatened by the development of drug resistance to mono therapies necessitating revisions of treatment policies. In this regard, in 2002 Ghana initiated the process of using ACTs following WHO recommendations for all Antimalarial resistance is common. Anti-malarial drug resistance has been defined as: "the ability of a parasite to survive and/or multiply despite the administration and absorption of a drug given in doses equal to or higher than those usually recommended but within tolerance of the subject. The drug in question must gain access to the Recent gains in preventing the disease in pregnancy may be lost as resistance to prophylactic treatment rises. Malaria in pregnancy now complicated by drug resistance | CIDRAP The Cambodian Malaria Elimination Action Framework 2016-2020 has the ultimate goal of national elimination of P. falciparum and multidrug-resistant malaria by 2020. In 2016, Cambodia moved from control to elimination activities concentrated in 18 operational districts in the northwest of Cambodia. Since the first reports of chloroquine-resistant falciparum malaria in southeast Asia and South America almost half a century ago, drug-resistant malaria has posed a major problem in malaria control. By the late 1980s, resistance to sulfadoxine-pyrimethamine and to mefloquine was also prevalent on the Thai-Cambodian and Thai-Myanmar (Thai-Burmese) borders, rendering them established multidrug malaria vary, depending on the severity of the disease; fast-acting, parenteral drugs are best for severe, life-threatening disease. In addition, treatment protocols for falciparum malaria vary geographically and depend on the resistance profiles for strains